Impax Laboratories Company Profile (NASDAQ:IPXL)

About Impax Laboratories (NASDAQ:IPXL)

Impax Laboratories logoImpax Laboratories, Inc. is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and marketing of bioequivalent pharmaceutical products (generics), in addition to the development and marketing of branded products. Its segments include Impax Generics and Impax Specialty Pharma. The Impax Generics segment is focused on the development, manufacture, sale and distribution of its generic products, which are the pharmaceutical and therapeutic equivalents of brand-name drug products and are marketed under their established drug names. The Impax Specialty Pharma segment is engaged in the promotion, sale and distribution of several branded products, including its branded pharmaceutical product, Rytary, an extended release oral capsule formulation of carbidopa-levodopa for the treatment of Parkinson's disease, post-encephalitic Parkinsonism and Parkinsonism, and Zomig (zolmitriptan) products, indicated for the treatment of migraine headaches.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Pharmaceuticals
  • Sub-Industry: Pharmaceuticals
  • Symbol: NASDAQ:IPXL
  • CUSIP: 45256B10
  • Web: www.impaxlabs.com
Capitalization:
  • Market Cap: $1.70919 billion
  • Outstanding Shares: 71,826,000
Average Prices:
  • 50 Day Moving Avg: $19.12
  • 200 Day Moving Avg: $15.63
  • 52 Week Range: $7.75 - $27.29
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 21.30
  • P/E Growth: 2.73
Sales & Book Value:
  • Annual Revenue: $812.82 million
  • Price / Sales: 2.03
  • Book Value: $7.32 per share
  • Price / Book: 3.14
Profitability:
  • EBIDTA: $144.42 million
  • Net Margins: -71.08%
  • Return on Equity: 9.05%
  • Return on Assets: 3.20%
Debt:
  • Debt-to-Equity Ratio: 1.46%
  • Current Ratio: 1.75%
  • Quick Ratio: 1.19%
Misc:
  • Average Volume: 1.61 million shs.
  • Beta: 1.17
  • Short Ratio: 4.78
 

Frequently Asked Questions for Impax Laboratories (NASDAQ:IPXL)

What is Impax Laboratories' stock symbol?

Impax Laboratories trades on the NASDAQ under the ticker symbol "IPXL."

How were Impax Laboratories' earnings last quarter?

Impax Laboratories, Inc. (NASDAQ:IPXL) released its quarterly earnings results on Wednesday, August, 9th. The company reported $0.18 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.14 by $0.04. The business had revenue of $202.08 million for the quarter, compared to the consensus estimate of $195.62 million. Impax Laboratories had a negative net margin of 71.08% and a positive return on equity of 9.05%. The business's revenue was up 17.1% on a year-over-year basis. During the same period in the previous year, the firm earned $0.21 EPS. View Impax Laboratories' Earnings History.

When will Impax Laboratories make its next earnings announcement?

Impax Laboratories is scheduled to release their next quarterly earnings announcement on Tuesday, November, 7th 2017. View Earnings Estimates for Impax Laboratories.

What guidance has Impax Laboratories issued on next quarter's earnings?

Impax Laboratories issued an update on its FY17 earnings guidance on Wednesday, August, 9th. The company provided earnings per share guidance of $0.55-0.70 for the period, compared to the Thomson Reuters consensus estimate of $0.66.

Where is Impax Laboratories' stock going? Where will Impax Laboratories' stock price be in 2017?

15 equities research analysts have issued twelve-month target prices for Impax Laboratories' shares. Their predictions range from $10.00 to $27.00. On average, they anticipate Impax Laboratories' share price to reach $20.07 in the next twelve months. View Analyst Ratings for Impax Laboratories.

What are analysts saying about Impax Laboratories stock?

Here are some recent quotes from research analysts about Impax Laboratories stock:

  • 1. Cantor Fitzgerald analysts commented, "We are raising our PT for IPXL shares to $25 from $20, and maintaining our Overweight rating for the stock. The increase in our PT is driven by multiple expansion. After speaking to the company, we believe that the company’s execution of its stated business objectives continues to meet or beat our expectations." (9/6/2017)
  • 2. According to Zacks Investment Research, "Impax’s Generics segment has been under competitive and pricing pressure, which is expected to persist through 2017. However, the epinephrine auto-injector sales picked up and the company has 24 ANDAs pending FDA approval. The company is also taking steps to reduce costs and improve efficiencies, which is estimated to save a total of $130 million by the end of 2019. However, the company’s 2017 earnings guidance is significantly lower than 2016 numbers as continued impact of lower pricing on generics is expected to hurt revenues. Moreover, the company’s manufacturing facilities had been hampered by quality control issues since 2011 and an inspection had even delayed Rytary’s approval. Impax is also involved in a patent litigation regarding approval of generic version of Rytary. Estimates have been mostly stable ahead of the Q2 results. Impax does not have an impressive record of earnings surprises in the recent quarters." (7/24/2017)
  • 3. Guggenheim analysts commented, "Impax (IPXL, BUY, $12.70) named Paul Bisaro as its new, full-time CEO earlier today, which increases our confidence that there could be upside to consensus expectations in '17+. Bisaro has 25 years of generic and branded pharma experience, with an impressive track record of execution and transformation at companies like Allergan (AGN, NEUTRAL, $237.33) and its predecessors and Barr Pharmaceuticals (acquired by TEVA [BUY, $32.76] in 2010). Bisaro is also on the Board of Directors of AGN and Zoetis (ZTS, BUY, $53.85)." (3/27/2017)
  • 4. Royal Bank Of Canada analysts commented, "The stock was down -35% following IPXL's 4Q results and first-time 2017 update (no revenue or EPS given, as expected). We continue to see a number of generic headwinds that will linger as IPXL pursues a leadership change and what we see as needed review of strategic positioning. We lower EPS and target to reflect continued challenges. Remain Sector Perform." (3/2/2017)

Are investors shorting Impax Laboratories?

Impax Laboratories saw a increase in short interest in August. As of August 15th, there was short interest totalling 8,583,256 shares, an increase of 25.7% from the July 31st total of 6,830,967 shares. Based on an average trading volume of 2,654,227 shares, the days-to-cover ratio is presently 3.2 days. Approximately 11.9% of the company's stock are sold short.

Who are some of Impax Laboratories' key competitors?

Who are Impax Laboratories' key executives?

Impax Laboratories' management team includes the folowing people:

  • Robert L. Burr, Independent Chairman of the Board
  • Paul M. Bisaro, President, Chief Executive Officer, Director
  • Bryan M. Reasons, Chief Financial Officer, Senior Vice President - Finance
  • Douglas S. Boothe, President - Generics Division
  • Michael J. Nestor, President - Impax Specialty Pharmaceutical Division
  • Mark A. Schlossberg Esq., Senior Vice President, General Counsel, Corporate Secretary
  • Jeffrey D. Nornhold, Senior Vice President - Technical Operations
  • J. Kevin Buchi, Director
  • Janet S. Vergis, Director
  • Leslie Z. Benet Ph.D., Independent Director

Who owns Impax Laboratories stock?

Impax Laboratories' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Maverick Capital Ltd. (9.63%), Vanguard Group Inc. (9.53%), SHANGHAI FOSUN PHARMACEUTICAL (GROUP) COMPANY ., LTD. (5.19%), Dimensional Fund Advisors LP (4.53%), Frontier Capital Management Co. LLC (2.21%) and Balyasny Asset Management LLC (1.41%). Company insiders that own Impax Laboratories stock include Leslie Z Benet and Michael Nestor. View Institutional Ownership Trends for Impax Laboratories.

Who sold Impax Laboratories stock? Who is selling Impax Laboratories stock?

Impax Laboratories' stock was sold by a variety of institutional investors in the last quarter, including North Tide Capital LLC, Federated Investors Inc. PA, Thrivent Financial For Lutherans, Canada Pension Plan Investment Board, Quantitative Investment Management LLC, Penn Capital Management Co. Inc., OxFORD Asset Management LLP and Icon Advisers Inc. Co.. View Insider Buying and Selling for Impax Laboratories.

Who bought Impax Laboratories stock? Who is buying Impax Laboratories stock?

Impax Laboratories' stock was purchased by a variety of institutional investors in the last quarter, including Maverick Capital Ltd., Balyasny Asset Management LLC, Stifel Financial Corp, Dimensional Fund Advisors LP, Vanguard Group Inc., Nexthera Capital LP, Frontier Capital Management Co. LLC and State of Wisconsin Investment Board. View Insider Buying and Selling for Impax Laboratories.

How do I buy Impax Laboratories stock?

Shares of Impax Laboratories can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Impax Laboratories' stock price today?

One share of Impax Laboratories stock can currently be purchased for approximately $23.00.


MarketBeat Community Rating for Impax Laboratories (NASDAQ IPXL)
Community Ranking:  2.0 out of 5 (star star)
Outperform Votes:  269 (Vote Outperform)
Underperform Votes:  413 (Vote Underperform)
Total Votes:  682
MarketBeat's community ratings are surveys of what our community members think about Impax Laboratories and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Impax Laboratories (NASDAQ:IPXL) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Sell Rating, 9 Hold Ratings, 5 Buy Ratings
Consensus Rating:Hold (Score: 2.27)
Consensus Price Target: $20.07 (12.75% downside)

Analysts' Ratings History for Impax Laboratories (NASDAQ:IPXL)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/23/2017BTIG ResearchReiterated RatingBuy$20.00 -> $27.00LowView Rating Details
9/19/2017Deutsche Bank AGReiterated RatingBuy$23.00LowView Rating Details
9/19/2017Citigroup Inc.Boost Price TargetBuy$23.00LowView Rating Details
9/17/2017Piper Jaffray CompaniesReiterated RatingHold$17.00LowView Rating Details
9/11/2017Cantor FitzgeraldBoost Price TargetOverweight$20.00 -> $25.00MediumView Rating Details
8/10/2017Royal Bank Of CanadaSet Price TargetHold$15.00 -> $17.00LowView Rating Details
8/9/2017Canaccord GenuitySet Price TargetHold$19.00HighView Rating Details
8/9/2017Cowen and CompanySet Price TargetHold$12.00 -> $20.00HighView Rating Details
6/23/2017BMO Capital MarketsReiterated RatingHold$16.00LowView Rating Details
6/12/2017Janney Montgomery ScottReiterated RatingNeutral$21.00HighView Rating Details
3/27/2017GuggenheimReiterated RatingBuy$20.00LowView Rating Details
3/8/2017Susquehanna Bancshares IncDowngradePositive -> Neutral$18.00 -> $10.00LowView Rating Details
11/14/2016WallachBeth CapitalDowngradeBuy -> Hold$30.00 -> $18.00N/AView Rating Details
11/7/2016Bank of America CorporationDowngradeNeutral -> Underperform$19.00N/AView Rating Details
9/27/2016Goldman Sachs Group, Inc. (The)UpgradeSell -> Neutral$25.00 -> $26.00N/AView Rating Details
8/15/2016Northland SecuritiesUpgradeMarket Perform -> Outperform$30.00N/AView Rating Details
8/10/2016Leerink SwannLower Price TargetMarket Perform$33.00 -> $24.00N/AView Rating Details
6/1/2016J P Morgan Chase & CoInitiated CoverageNeutral$47.00N/AView Rating Details
3/2/2016NomuraReiterated RatingHoldN/AView Rating Details
2/17/2016Raymond James Financial, Inc.UpgradeUnderperform -> Market PerformN/AView Rating Details
(Data available from 9/25/2015 forward)

Earnings

Earnings History for Impax Laboratories (NASDAQ:IPXL)
Earnings by Quarter for Impax Laboratories (NASDAQ:IPXL)
Earnings History by Quarter for Impax Laboratories (NASDAQ IPXL)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/7/2017$0.20N/AView Earnings Details
8/9/2017Q2 2017$0.14$0.18$195.62 million$202.08 millionViewListenView Earnings Details
5/10/2017Q1 2017$0.12$0.11$193.17 million$184.40 millionViewN/AView Earnings Details
3/1/2017Q416$0.16$0.16$219.54 million$198.40 millionViewListenView Earnings Details
11/9/2016Q316$0.40$0.37$234.87 million$228.00 millionViewListenView Earnings Details
8/9/2016Q216$0.32$0.21$223.67 million$173.00 millionViewN/AView Earnings Details
5/10/2016Q116$0.39$0.43$241.84 million$226.00 millionViewListenView Earnings Details
2/22/2016Q415$0.44$0.62$223.23 million$282.10 millionViewListenView Earnings Details
11/9/2015Q315$0.39$0.40$214.69 million$221.10 millionViewN/AView Earnings Details
8/10/2015Q215$0.35$0.34$200.68 million$214.20 millionViewListenView Earnings Details
5/11/2015Q115$0.18$0.09$146.00 million$143.10 millionViewListenView Earnings Details
2/24/2015Q414$0.11$0.16$125.50 million$131.20 millionViewN/AView Earnings Details
11/4/2014Q314$0.31$0.33$148.36 million$145.63 millionViewN/AView Earnings Details
8/6/2014Q214$0.39$0.60$155.97 million$188.10 millionViewN/AView Earnings Details
5/1/2014Q114$0.13$0.24$97.80 million$118.70 millionViewN/AView Earnings Details
2/20/2014Q413$0.03($0.14)$119.01 million$100.74 millionViewN/AView Earnings Details
11/4/2013Q313($0.08)$0.25$111.83 million$115.75 millionViewN/AView Earnings Details
8/8/2013Q2 2013$0.04$0.08$120.75 million$129.63 millionViewN/AView Earnings Details
5/1/2013Q1 2013$0.21$0.37$129.12 million$148.50 millionViewN/AView Earnings Details
2/25/2013Q4 2012$0.19$0.30$127.03 million$141.10 millionViewN/AView Earnings Details
10/30/2012Q312$0.49$0.48$160.76 million$145.60 millionViewN/AView Earnings Details
7/31/2012$0.44$0.60ViewN/AView Earnings Details
5/1/2012$0.45$0.52ViewN/AView Earnings Details
2/28/2012$0.19$0.33ViewN/AView Earnings Details
11/1/2011$0.20$0.30ViewN/AView Earnings Details
8/2/2011$0.18$0.19ViewN/AView Earnings Details
5/3/2011$0.15$0.21ViewN/AView Earnings Details
2/24/2011$0.22$0.23ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Impax Laboratories (NASDAQ:IPXL)
2017 EPS Consensus Estimate: $0.87
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171$0.13$0.13$0.13
Q2 20171$0.17$0.17$0.17
Q3 20171$0.22$0.22$0.22
Q4 20171$0.35$0.35$0.35
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Impax Laboratories (NASDAQ:IPXL)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Impax Laboratories (NASDAQ:IPXL)
Insider Ownership Percentage: 3.20%
Institutional Ownership Percentage: 86.26%
Insider Trades by Quarter for Impax Laboratories (NASDAQ:IPXL)
Institutional Ownership by Quarter for Impax Laboratories (NASDAQ:IPXL)
Insider Trades by Quarter for Impax Laboratories (NASDAQ:IPXL)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/31/2017Michael NestorInsiderSell1,130$15.00$16,950.00View SEC Filing  
5/17/2017Michael NestorInsiderSell857$16.48$14,123.36View SEC Filing  
5/12/2017Michael NestorInsiderSell700$17.11$11,977.00View SEC Filing  
8/15/2016Leslie Z BenetDirectorSell10,092$22.81$230,198.52View SEC Filing  
9/11/2015Mark A SchlossbergSVPSell7,457$43.30$322,888.10View SEC Filing  
9/10/2015Michael NestorInsiderSell5,000$43.56$217,800.00View SEC Filing  
8/31/2015Michael MarkbreiterDirectorSell28,000$41.70$1,167,600.00View SEC Filing  
8/27/2015Mark A SchlossbergSVPSell4,649$43.41$201,813.09View SEC Filing  
8/27/2015Peter R TerreriDirectorSell4,833$43.93$212,313.69View SEC Filing  
8/26/2015Michael MarkbreiterDirectorSell19,399$42.24$819,413.76View SEC Filing  
6/6/2014Larry HsuDirectorSell100,000$28.38$2,838,000.00View SEC Filing  
5/27/2014Peter R TerreriDirectorSell3,000$28.00$84,000.00View SEC Filing  
5/22/2014Larry HsuDirectorSell50,000$27.22$1,361,000.00View SEC Filing  
5/21/2014Larry HsuDirectorSell3,800$26.53$100,814.00View SEC Filing  
5/16/2014Nigel FlemingDirectorSell1,900$25.72$48,868.00View SEC Filing  
5/12/2014Nigel FlemingDirectorSell1,333$26.58$35,431.14View SEC Filing  
5/8/2014Michael MarkbreiterDirectorSell12,500$26.44$330,500.00View SEC Filing  
5/6/2014Larry HsuDirectorSell219,386$26.28$5,765,464.08View SEC Filing  
3/11/2014Michael MarkbreiterDirectorSell4,000$27.54$110,160.00View SEC Filing  
1/8/2014Robert BurrDirectorSell1,500$24.31$36,465.00View SEC Filing  
11/13/2013Robert BurrDirectorSell1,500$22.98$34,470.00View SEC Filing  
10/9/2013Robert BurrDirectorSell1,500$20.10$30,150.00View SEC Filing  
9/11/2013Robert BurrDirectorSell1,500$20.87$31,305.00View SEC Filing  
8/14/2013Robert BurrDirectorSell1,500$21.15$31,725.00View SEC Filing  
7/10/2013Robert L BurrDirectorSell1,500$20.26$30,390.00View SEC Filing  
6/12/2013Robert L BurrDirectorSell1,500$18.80$28,200.00View SEC Filing  
5/8/2013Robert L BurrDirectorSell1,500$16.35$24,525.00View SEC Filing  
5/1/2013Peter R TerreriDirectorSell3,450$17.39$59,995.50View SEC Filing  
3/12/2013Larry HsuCEOBuy7,000$16.88$118,160.00View SEC Filing  
3/12/2013Mark A SchlossbergSVPBuy1,000$16.73$16,730.00View SEC Filing  
2/13/2013Robert L BurrDirectorSell1,500$19.82$29,730.00View SEC Filing  
11/14/2012Robert L BurrDirectorSell1,500$19.86$29,790.00View SEC Filing  
8/20/2012Nigel FlemingDirectorSell6,000$23.99$143,940.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Impax Laboratories (NASDAQ:IPXL)
Latest Headlines for Impax Laboratories (NASDAQ:IPXL)
Source:
DateHeadline
americanbankingnews.com logoImpax Laboratories, Inc. (IPXL) Price Target Increased to $23.00 by Analysts at Citigroup Inc.
www.americanbankingnews.com - September 24 at 1:00 PM
americanbankingnews.com logoImpax Laboratories, Inc. (IPXL) Stock Rating Reaffirmed by BTIG Research
www.americanbankingnews.com - September 23 at 5:58 PM
americanbankingnews.com logoHead to Head Contrast: Impax Laboratories (IPXL) vs. Its Competitors
www.americanbankingnews.com - September 23 at 4:20 PM
americanbankingnews.com logoImpax Laboratories (IPXL) vs. Aquinox Pharmaceuticals (AQXP) Head-To-Head Review
www.americanbankingnews.com - September 23 at 8:32 AM
reuters.com logoGeneric drugmaker Impax Labs in talks to merge with Amneal: WSJ
www.reuters.com - September 22 at 1:46 PM
rttnews.com logoImpax Laboratories Inc. (IPXL) Surged On Reports Of Merger Talks
www.rttnews.com - September 22 at 1:46 PM
finance.yahoo.com logoShould You Buy Impax Laboratories Inc (IPXL) Now?
finance.yahoo.com - September 22 at 1:46 PM
finance.yahoo.com logo[$$] Impax Laboratories in Talks to Merge With Amneal Pharmaceuticals
finance.yahoo.com - September 22 at 1:46 PM
americanbankingnews.com logoImpax Laboratories' (IPXL) "Buy" Rating Reiterated at Deutsche Bank AG
www.americanbankingnews.com - September 19 at 3:52 PM
americanbankingnews.com logoImpax Laboratories' (IPXL) "Hold" Rating Reiterated at Piper Jaffray Companies
www.americanbankingnews.com - September 17 at 7:06 AM
americanbankingnews.com logoImpax Laboratories, Inc. (IPXL) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - September 16 at 1:02 PM
americanbankingnews.com logoCantor Fitzgerald Increases Impax Laboratories, Inc. (IPXL) Price Target to $25.00
www.americanbankingnews.com - September 11 at 11:59 AM
americanbankingnews.com logoImpax Laboratories, Inc. (IPXL) Earns "Buy" Rating from Cantor Fitzgerald
www.americanbankingnews.com - September 7 at 3:26 PM
finance.yahoo.com logoImpax to Present at the Morgan Stanley 15th Annual Global Healthcare Conference
finance.yahoo.com - September 5 at 4:44 PM
americanbankingnews.com logo$203.16 Million in Sales Expected for Impax Laboratories, Inc. (IPXL) This Quarter
www.americanbankingnews.com - August 31 at 9:38 AM
americanbankingnews.com logoImpax Laboratories, Inc. (IPXL) Short Interest Up 25.7% in August
www.americanbankingnews.com - August 26 at 1:20 AM
americanbankingnews.com logoImpax Laboratories, Inc. (IPXL) Given Average Recommendation of "Hold" by Analysts
www.americanbankingnews.com - August 22 at 12:50 PM
finance.yahoo.com logoImpax Laboratories, Inc. – Value Analysis (NASDAQ:IPXL) : August 19, 2017
finance.yahoo.com - August 19 at 12:49 AM
americanbankingnews.com logoImpax Laboratories (IPXL) and Amicus Therapeutics (FOLD) Head-To-Head Review
www.americanbankingnews.com - August 15 at 12:38 PM
americanbankingnews.com logoFY2017 EPS Estimates for Impax Laboratories, Inc. (NASDAQ:IPXL) Cut by Analyst
www.americanbankingnews.com - August 14 at 5:32 AM
fool.com logoWhy Impax Laboratories Inc Is Up for a Second Straight Day
www.fool.com - August 10 at 5:37 PM
americanbankingnews.com logoHead to Head Review: Impax Laboratories (NASDAQ:IPXL) vs. Horizon Pharma PLC (HZNP)
www.americanbankingnews.com - August 10 at 5:16 PM
americanbankingnews.com logoRoyal Bank Of Canada Reaffirms "Sector Perform" Rating for Impax Laboratories, Inc. (NASDAQ:IPXL)
www.americanbankingnews.com - August 10 at 3:22 PM
finance.yahoo.com logoImpax Reports Solid Second Quarter 2017 Results with Total Revenues Increasing 17% to $202 Million
finance.yahoo.com - August 9 at 8:14 PM
americanbankingnews.com logoImpax Laboratories, Inc. (NASDAQ:IPXL) Announces Earnings Results
www.americanbankingnews.com - August 9 at 7:48 PM
americanbankingnews.com logoCantor Fitzgerald Analysts Give Impax Laboratories, Inc. (IPXL) a $20.00 Price Target
www.americanbankingnews.com - August 9 at 6:46 PM
fool.com logoWhy Impax Laboratories Inc Jumped Higher Today
www.fool.com - August 9 at 12:55 PM
americanbankingnews.com logoImpax Laboratories, Inc. (NASDAQ:IPXL) Updates FY17 Earnings Guidance
www.americanbankingnews.com - August 9 at 8:46 AM
fool.com logoHere's Why Impax Laboratories Inc Jumped 18% In July
www.fool.com - August 7 at 11:13 AM
americanbankingnews.com logoImpax Laboratories, Inc. (NASDAQ:IPXL) Cut to Hold at BidaskClub
www.americanbankingnews.com - August 4 at 11:16 PM
americanbankingnews.com logoImpax Laboratories, Inc. (NASDAQ:IPXL) Receives Average Recommendation of "Hold" from Analysts
www.americanbankingnews.com - July 28 at 12:55 PM
americanbankingnews.com logoImpax Laboratories, Inc. (IPXL) Cut to Strong Sell at Zacks Investment Research
www.americanbankingnews.com - July 24 at 1:04 PM
americanbankingnews.com logoZacks: Brokerages Expect Impax Laboratories, Inc. (IPXL) Will Post Quarterly Sales of $196.18 Million
www.americanbankingnews.com - July 23 at 9:18 AM
americanbankingnews.com logo$0.14 EPS Expected for Impax Laboratories, Inc. (IPXL) This Quarter
www.americanbankingnews.com - July 21 at 12:32 PM
finance.yahoo.com logoBiotech Movers: Impax Shares Jump on FDA Approval for Generic Version of Concerta
finance.yahoo.com - July 18 at 4:50 PM
americanbankingnews.com logoImpax Laboratories, Inc. (NASDAQ:IPXL) Price Target Raised to $21.00
www.americanbankingnews.com - July 17 at 7:15 PM
americanbankingnews.com logoImpax Laboratories, Inc. (NASDAQ:IPXL) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - July 17 at 3:28 PM
americanbankingnews.com logoImpax Laboratories, Inc. (NASDAQ:IPXL) Given "Hold" Rating at Royal Bank Of Canada
www.americanbankingnews.com - July 16 at 7:32 AM
americanbankingnews.com logoImpax Laboratories, Inc. (NASDAQ:IPXL) Lifted to Buy at Zacks Investment Research
www.americanbankingnews.com - July 11 at 4:52 PM
americanbankingnews.com logoCantor Fitzgerald Comments on Impax Laboratories, Inc.'s FY2017 Earnings (NASDAQ:IPXL)
www.americanbankingnews.com - July 6 at 9:16 AM
finance.yahoo.com logoImpax Announces FDA Approval and Launch of Additional Strengths of Generic Focalin XR® (Dexmethylphenidate Hydrochloride) Extended-Release Capsules CII
finance.yahoo.com - July 6 at 6:35 AM
americanbankingnews.com logoImpax Laboratories, Inc. (NASDAQ:IPXL) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - July 3 at 10:59 AM
americanbankingnews.com logo Brokerages Expect Impax Laboratories, Inc. (IPXL) Will Post Quarterly Sales of $196.18 Million
www.americanbankingnews.com - June 29 at 11:42 AM
americanbankingnews.com logoImpax Laboratories, Inc. (IPXL) Short Interest Update
www.americanbankingnews.com - June 29 at 7:14 AM
americanbankingnews.com logo Analysts Anticipate Impax Laboratories, Inc. (IPXL) to Announce $0.14 EPS
www.americanbankingnews.com - June 27 at 8:32 AM
americanbankingnews.com logoImpax Laboratories' (IPXL) "Hold" Rating Reaffirmed at BMO Capital Markets
www.americanbankingnews.com - June 24 at 9:34 AM
finance.yahoo.com logoToday's Research Reports on Stocks to Watch: Agenus and Impax Laboratories
finance.yahoo.com - June 21 at 3:40 PM
americanbankingnews.com logoImpax Laboratories' (IPXL) "Hold" Rating Reiterated at Royal Bank Of Canada
www.americanbankingnews.com - June 18 at 8:20 PM
americanbankingnews.com logoImpax Laboratories, Inc. (IPXL) Now Covered by Cantor Fitzgerald
www.americanbankingnews.com - June 16 at 10:06 AM
finance.yahoo.com logoImpax Laboratories, Inc. breached its 50 day moving average in a Bearish Manner : IPXL-US : June 15, 2017
finance.yahoo.com - June 16 at 6:13 AM

Social

Chart

Impax Laboratories (IPXL) Chart for Monday, September, 25, 2017

This page was last updated on 9/25/2017 by MarketBeat.com Staff